BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
cell-cell adhesion
,
Obesity
,
Embryo
,
Amniocentesis
,
Doxycycline
,
rs2300478
,
TGFB1
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
AKT3
(gene)
Summary
General Info
Body Atlas
Most Correlated Tissues
Fetal brain
Cerebellar vermis
Saphenous vein
Cerebellum
Thalamus lateral nuclei
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
Loading...
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
Loading...
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
Loading...
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
Loading...
Explore Curated Studies Results
Literature
Most Relevant Literature
Activity-induced synaptic structural modifications by Akt.
A multi-layered network model identifies Akt1 as a common modulator of neurodegeneration.
Identification of XAF1 as an endogenous AKT inhibitor.
Redundant roles of AKT1 and AKT2 in fertility, estrous cyclicity and endometrial gland development.
Enhanced Akt3 kinase activity reduces atherosclerosis in hyperlipidemic mice in a gender-dependent m…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer
Dose Defining Study For MK-2206 Combined With Gefitinib In Non Small Cell Lung Cancer (NSCLC)
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ